1. Cañellas-Socias, Adrià, Cortina, Carme, Hernando-Momblona, Xavier, Attolini, Camille Stephan-Otto, Batlle, Eduard. 2022. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. In Nature, 611, 603-613. doi:10.1038/s41586-022-05402-9. https://pubmed.ncbi.nlm.nih.gov/36352230/
2. Zeng, Qingsong, Yi, Cunjian, Lu, Jinzhi, Chen, Keming, Hong, Li. 2023. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis. In Cancer medicine, 12, 9024-9040. doi:10.1002/cam4.5637. https://pubmed.ncbi.nlm.nih.gov/36708070/
3. Li, Jinqiao, Liu, Jianyu, Wang, Honglei, Wang, Yueze, Xu, Wanhai. 2023. Single-cell analyses EMP1 as a marker of the ratio of M1/M2 macrophages is associated with EMT, immune infiltration, and prognosis in bladder cancer. In Bladder (San Francisco, Calif.), 10, e21200011. doi:10.14440/bladder.2023.852. https://pubmed.ncbi.nlm.nih.gov/38163006/
4. Van Camp, Laurens, Depreter, Barbara, De Wilde, Jilke, Lammens, Tim, De Moerloose, Barbara. 2024. Acute myeloid leukemia stem cell signature gene EMP1 is not an eligible therapeutic target. In Pediatric research, 97, 160-168. doi:10.1038/s41390-024-03341-x. https://pubmed.ncbi.nlm.nih.gov/38879624/
5. Zhang, Jun, Yang, Jing, Li, Xing, Liu, Yi, Bao, Yindi. 2024. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer. In Molecular genetics and genomics : MGG, 299, 51. doi:10.1007/s00438-024-02146-1. https://pubmed.ncbi.nlm.nih.gov/38743077/
智鼠故事 
